Fulcrum Therapeutics

Fulcrum's sickle cell disease program is back in business after FDA lifts 6-month hold
Fulcrum's sickle cell disease program is back in business after FDA lifts 6-month hold
Fierce Biotech
Fulcrum Therapeutics
sickle cell disease
clinical trials
FDX-6058
Flag link:
FDA placed hold on Fulcrum's sickle cell therapy over hematological malignancy concerns
FDA placed hold on Fulcrum's sickle cell therapy over hematological malignancy concerns
Fierce Biotech
FDA
Fulcrum Therapeutics
sickle cell therapy
FDX-6058
clinical hold
Flag link:
With CEO search, PhIII study underway, Fulcrum Therapeutics raises $125M from stock offering
With CEO search, PhIII study underway, Fulcrum Therapeutics raises $125M from stock offering
Endpoints
Fulcrum Therapeutics
Pharma CEOs
Flag link:
Aiming to brush last year's flop aside, Fulcrum sees shares skyrocket on early look at sickle cell program
Aiming to brush last year's flop aside, Fulcrum sees shares skyrocket on early look at sickle cell program
Endpoints
Fulcrum Therapeutics
GSK
clinical trials
FTX-6058
Flag link:
Second-quarter catalysts for the smaller players
Second-quarter catalysts for the smaller players
EP Vantage
AC Immune
Anavex
Santhera
IMMUTEP
Syndax
Novan
Fulcrum Therapeutics
BeyondSpring
Corbus
Orphazyme
Aldeyra
Adaptimmune
Inflarx
Sutro
Gemini Therapeutics
Flag link:
Fulcrum under pressure on underwhelming losmapimod data in type of muscular dystrophy
Fulcrum under pressure on underwhelming losmapimod data in type of muscular dystrophy
Seeking Alpha
Fulcrum Therapeutics
clinical trials
losmapimod
FSHD
Flag link:
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Acceleron signs pulmonary research and discovery deal with Fulcrum Therapeutics
Pharmaceutical Business Review
Acceleron
Fulcrum Therapeutics
R&D
small molecule drugs
pulmonary
Flag link:
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
The Week Ahead In Biotech: Johnson & Johnson Kickstarts Big Pharma Earnings
Yahoo/Benzinga
Merck
relebactam
TapImmune
earnings
JNJ
Seattle Genetics
Abbott Labs
Intuitive Surgical
Mirum Pharmaceuticals
Fulcrum Therapeutics
Genmab
Flag link:
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
CP Wire
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
Flag link:
Genetic Disease Focused Fulcrum Therapeutics Files for $86 Million IPO
Fulcrum Therapeutics
IPOs
FSHD
sickle cell disease
beta thalassemia
Flag link:
GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind
GSK punts a failed cardio drug to a biotech startup — which has a new development strategy in mind
Endpoints
GSK
losmapimod
Fulcrum Therapeutics
Flag link:
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO
Working with Patients and a Fresh $80M, Fulcrum Eyes a 2019 IPO
Xconomy
Fulcrum Therapeutics
IPOs
FSHD
Flag link: